LeadXpro AG, a lead discovery start-up focusing on membrane protein drug targets, announced the selection of the Creoptix WAVE technology by the young Swiss company Creaoptix. The system will strengthen leadXpro's capabilities for drug discovery aimed at identifying and optimizing drug candidates directed against challenging membrane protein drug targets.
LeadXpro will receive the Creoptix WAVEdelta system, which is Creoptix’s latest technology for real-time label-free molecular interaction analysis. The WAVEdelta combines highest sensitivity and the broadest sample compatibility, which is especially important when working with membrane proteins.
“LeadXpro scientists are experts in the field of membrane protein drug targets and they rigorously evaluated our system against several competitors. It makes us very proud that they selected the Creoptix WAVEdelta as their system to analyse kinetics and affinity in real-time,” said Matyas Vegh, CEO of Creoptix.
LeadXpro will combine the WAVE technology with its expertise in assay development, high throughput screening, membrane protein generation, structure determination and application of further biophysical methods. Accurate characterization of the speed at which drug molecule bind to and dissociate from their therapeutic target helps fine-tuning the design of new drug molecules. LeadXpro researchers will investigate the interaction of small molecules and biotherapeutics with ion channels, transporters and G-protein receptors to facilitate the discovery and optimization of novel drug lead molecules.
“The combination of unique technology, robustness, flexibility in designing a broad range of assays and high sensitivity, enabling even fragment sized molecules to be screened and characterized, made the Creoptix WAVEdelta the instrument investment of our choice. Thorough testing in our laboratory has convinced us that Creoptix’ WAVE technology aids us best in discovering better drug molecules.” Nicolas Bocquet, Senior Scientist at leadXpro
About leadXpro AG
Established in 2015 at PARK innovAARE in Villigen (AG), leadXpro is a lead discovery company focusing on membrane protein drug targets. The company is committed to the application of biophysical and structure-based methods for the discovery and optimization of next generation lead compounds for challenging GPCR’s, ion-channels and transporters. It capitalize on the knowledge regarding membrane protein generation, structural biology and facilities of the Paul Scherrer Institute (PSI) with premium access to the synchrotron Swiss Light Source (SLS) and the Free Electron Laser (SwissFEL). Core expertise beyond X-ray include single particle cryo-electron microscopy (cryo-EM).
About Creoptix
Creoptix is a privately-held company founded in 2009 and headquartered in Wädenswil (ZH) and has offices near Boston, US. Creoptix focuses on the development of next generation instruments for the high-sensitivity kinetics and affinity analysis of label-free molecular interactions based on innovative, proprietary technology. Based on proprietary technology, the Creoptix WAVE systems provide exceptionally high sensitivity and resolution at even very low signal levels, fastest kinetics and a compatibility with crude samples like undiluted serum or plasma, cell supernatant, crude membrane extracts or large particles like viruses, VLPs or liposomes.
(press release)
Please login or sign up to comment.
Commenting guidelines